Updated on 10 July 2015
Japanese pharma majors Eli Lilly Japan K.K. and Sumitomo Dainippon Pharma Co. Ltd have signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist Trulicity Subcutaneous Injection 0.75 mg Ateos (Trulicity), for which Eli Lilly Japan obtained a manufacturing/marketing license as a drug indicated for type 2 diabetes, in Japan.
Based on this agreement, Eli Lilly Japan retains a manufacturing/marketing license for Trulicity and Sumitomo Dainippon Pharma takes responsibility for sales/distribution of the drug. Eli Lilly Japan and Sumitomo Dainippon Pharma will conduct activities to provide healthcare professionals with information regarding Trulicity.
Eli Lilly Japan and Sumitomo Dainippon Pharma have a plan to make a further contribution to the treatment of type 2 diabetes by building a close cooperative relationship through the sales collaboration of Trulicity.